BackTurnstone Biologics Overview
Turnstone Biologics Corp

Turnstone Biologics Debt to Equity

Turnstone Biologics (TSBX) has a debt-to-equity ratio of 0.03, below the sector sector average of 0.2.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.03

Debt to Equity

0.03

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Turnstone Biologics (TSBX) FAQ

The latest debt-to-equity ratio for TSBX is 0.03. That is below the sector sector average of 0.2. Investors often review this figure alongside Turnstone Biologics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, TSBX currently prints 0.03 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 86.1% below the sector mean. Large gaps often invite a closer look at Turnstone Biologics's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.03 for Turnstone Biologics is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with TSBX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting TSBX's debt-to-equity ratio (0.03), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.